Fossils found in North America reveal new species of 'very odd' sea monster: Scientists
A prehistoric sea monster never-before-known to man was hunting prey in North America 85 million years ago, fossils found decades ago in Canada reveal.
The first set of fossils, found in 1988 along the Puntledge River on Vancouver Island, were determined to belong to elasmosaurs, a genus of plesiosaur that lived in North America during the Late Cretaceous period, about 80.6 to 77 million years ago, according to the paper, published in the Journal of Systematic Palaeontology. Additional fossils found since include an isolated right humerus and a well-preserved juvenile skeleton comprising of a thorax, girdles and limbs, according to the study.
MORE: Evidence of 30-foot ancient sea monster found in Mississippi
But they have now been formally identified to belong to a "very odd" new genus of sea monster called Traskasaura sandrae, the researchers said.
The long-necked creature likely measured about 39 feet and had heavy, sharp teeth that were "ideal for crushing" ammonite shells, according to paleontologists. Dozens of well-preserved cervical vertebrae indicate at least 50 bones in the neck -- likely more, the researchers said.
T. sandrae also had a "strange mix" of primitive and derived traits, unlike any other elasmosaur. Its unique adaptations allowed it to hunt prey from above -- the first of the plesiosaur taxa to do so, the paper states.
Prey was likely abundant in the region at the time, the scientists said.
"It has a very odd mix of primitive and derived traits," O'Keefe said. "The shoulder, in particular, is unlike any other plesiosaur I have ever seen, and I have seen a few."
MORE: Underwater camera captures elusive tentacled creature 3 miles below ocean surface
When lead author F. Robin O'Keefe first saw the fossils and realized they belonged to an entirely new taxon, he hypothesized that they may be related to the plesiosaurs from Antarctica, he said in a statement. But it is "a strange, convergently evolved, fascinating beast," O'Keefe said.
"The fossil record is full of surprises," O'Keefe said. "It is always gratifying to discover something unexpected."
The fossils are among the most famous in the country. In 2002, they were adopted by the Province of British Columbia and declared the official fossil emblem of British Columbia.
"Plesiosaur fossils have been known for decades in British Columbia," O'Keefe said. "However, the identity of the animal that left the fossils has remained a mystery, even as it were declared BC's provincial fossil in 2023. Our new research, published today, finally solves this mystery."
MORE: What paleontologists learned from fossils of a 3-eyed predator that lived 500 million years ago
Paleontologists were reluctant at first to erect a new genus based solely on the adult skeleton of the elasmosaur. But a new 'excellently preserved' partial skeleton enabled this latest international team of scientists from Canada, Chile and the U.S. to eventually identify the new genus and species.
The genus name Traskasaura was given in honor of Courtenay, British Columbia, where the researchers who discovered the original specimen in 1988 were based. The species name sandrae honors Sandra Lee O'Keefe, a member of the team of researchers who identified the fossils in 2002.
They are currently on display at the Courtenay and District Museum and Palaeontology Centre in Courtenay, British Columbia.
Fossils found in North America reveal new species of 'very odd' sea monster: Scientists originally appeared on abcnews.go.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting
SHANGHAI, June 1, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel ("satri-cel", CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website The article in The Lancet was titled "Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial". Full article available at: The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled "Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician's choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)". Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, "The CT041-ST-01 trial represents the world's first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel's potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients' survival, and ultimately pursue potential cures." Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, "We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team's years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world's first commercially available CAR-T product for solid tumors, bringing benefits to patients." About Satri-cel Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595). Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China's NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA. About CARsgen Therapeutics Holdings Limited CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen's mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable. Forward-looking Statements All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group's current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group's control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading "Principal Risks and Uncertainties" in our most recent annual report and interim report and other announcements and reports made available on our corporate website, No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release. Contact CARsgen For more information, please visit View original content to download multimedia: SOURCE CARsgen Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo
14 hours ago
- Yahoo
Wanted in Berks: June 1, 2025
The Berks County sheriff's office is seeking the following fugitives: Janioshka Perez Janioshka Perez, 24, whose last known address was in the 600 block of Pine Street, Reading, is wanted on charges of theft by unlawful taking and retail theft. Spring Township police said Perez took five iPhones with a total value of more than $3,000 while she was employed at the AT&T Store on March 12. Police said Perez also took merchandise valued at about $153 from Target on March 28. She is described as 4 feet 11 inches and 175 pounds. William Schaeffer William Schaeffer, 66, whose last known address was in the 2100 block of Galen Hall Road, South Heidelberg Township, is wanted on charges he violated a protection-from-abuse order. South Heidelberg Township police said Schaeffer was at the victim's residence on March 12 and was sitting on a chair outside drinking a bottle of liquor with a loaded firearm within an arms reach on the bed of his truck. Schaeffer had been evicted from the residence under a protection-from-abuse order. The victim notified police, who responded and filed charges that day. He is described as 5 feet 10 inches and 195 pounds. Anyone with information about these fugitives is urged to contact the warrants division of the sheriff's department at 610-478-6390. Find the complete list of Berks County's most wanted at
Yahoo
19 hours ago
- Yahoo
The Samsung Galaxy S25+ is free with this AT&T trade-in deal
Carrier deals aren't always bad. Sure, you're locked into a longer-term commitment than you would be with an MVNO, but if you're used to staying with one company for years, there are benefits. Carrier discounts are a fantastic way to score a premium flagship smartphone for less, and if you catch one at the right time, you could even pay nothing. The Samsung Galaxy S25+ is an excellent device, and given its position in the company's lineup this year, I think it's the sensible choice for most people. AT&T wants you to pick up a Samsung Galaxy S25+ for free. You need to trade in an eligible phone and stay on an AT&T unlimited plan for 36 months, but if you were going to do that anyway, it's an excellent chance to save money on one of this year's best. I know the Samsung Galaxy S25 Edge is getting all the attention for being thin, but the Galaxy S25+ isn't exactly a thick smartphone. It's only 7.3mm thick and weighs only 190g — it's a joy to hold in your hand. It's also durable, with Gorilla Glass Victus 2 on the front and back, and an aluminum frame. The Galaxy S25+ features a gorgeous (and manageable) 6.7-inch AMOLED screen that refreshes at 120Hz. Samsung nailed the displays on this year's crop of Galaxy phones, and if you enjoy the saturated Samsung displays of old, you're going to love what you see on the Galaxy S25+. You won't be lacking in horsepower with the Galaxy S25+. Its Snapdragon 8 Elite chipset is precisely as advertised, with snappy performance and better power efficiency than I expected. I can get a full day of use and then some on a single charge from the phone's 4,900mAh battery. Camera performance is excellent, with sharp, crisp images and deep contrast from the phone's triple sensor setup. I wish the phone had the new 50MP ultrawide lens that the Galaxy S25 Ultra enjoys, but I can't complain. Of course, software is the centerpiece of this year's Galaxy S25+. I still don't understand the functions of Now Brief, but the Now Bar on One UI 7 is proving useful. I love using it to get sports scores and help with turn-by-turn navigation on Google Maps. In addition, it's hard to beat 7 years of software support and updates, meaning your Galaxy S25+ will get new features for years. All told, it's an excellent smartphone, and even better if you can pick one up for free.